Cannabidiol for ASD Open Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions
ASDAutism Spectrum Disorder
Interventions
DRUG

98% pure CBD

A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03900923 - Cannabidiol for ASD Open Trial | Biotech Hunter | Biotech Hunter